Back to discover
Drug

Cangrelor

Approved · FDA / EMA
Emerging researchLate-stage development

Also known as Kengreal.

RxNorm1656052ChEMBLCHEMBL334966UNII6AQ1Y404U7
1
Research papers
4
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: CANGRELOR (ANDA213703)

Regulatory2026-06-04FDA

The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens

Clinical trial2026-05-05Results expected Q3 2027 · ClinicalTrials.gov

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

Clinical trial2026-03-02Results expected Q1 2030 · ClinicalTrials.gov

Efficacy and Safety of Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction Related Cardiogenic Shock/Cardiac Arrest receiVIng VAECMO Support - a Phase 2, Single Arm, Single Center Trial

Clinical trial2025-10-29Primary completion · ClinicalTrials.gov

Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

Clinical trial2025-10-01Primary completion · ClinicalTrials.gov

The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial

Clinical trial2025-05-02Results posted · ClinicalTrials.gov

Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock

Clinical trial2025-04-01Completed · ClinicalTrials.gov

Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) Study

Clinical trial2024-03-20Results posted · ClinicalTrials.gov

Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment: The Switching Antiplatelet -5 (SWAP-5) Study

Clinical trial2023-05-16Results posted · ClinicalTrials.gov

Platelet Inhibition to Target Reperfusion Injury: The PITRI Trial

Clinical trial2022-12-01Primary completion · ClinicalTrials.gov

Approval: Kengrexal (EMA)

Regulatory2015-03-23EMA

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

Research2012-01-01JAMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Cangrelor
Aliases & brands
Kengreal
RxNorm CUI
1656052
ChEMBL ID
CHEMBL334966
UNII
6AQ1Y404U7
Regulatory jurisdictions
fdaema

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2015-03-23
Latest approval
2026-06-04
Authorities
FDA · EMA
Total events
2
fdaU.S. Food and Drug Administration· 1 event
2026-06-04Approval
Approval: CANGRELOR (ANDA213703)
Evidence ↗
emaEuropean Medicines Agency· 1 event
2015-03-23Approval
Approval: Kengrexal (EMA)
Indication: Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease… Show full indication

Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

24 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
24
registered trials across all phases
LATEST COMPLETION 2025
4
Active studies
4
Recruiting
14
Late-stage (III+)
14
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 24
Phase 13Phase 27Phase 33Phase 411

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens

RecruitingPH IVUniversity of Floridan=502027

Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

RecruitingPH IVFederico II Universityn=802026

Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock

CompletedPH IVFaculty Hospital Kralovske Vinohradyn=6052025

Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) Study

CompletedPH IVUniversity of Floridan=3592023

Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management

Unknown statusPH IVMedical University of Viennan=602021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock

CompletedPH IVFaculty Hospital Kralovske Vinohradyn=6052025

Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) Study

CompletedPH IVUniversity of Floridan=3592023

Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment: The Switching Antiplatelet -5 (SWAP-5) Study

CompletedPH IVUniversity of Floridan=222021

Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention

CompletedPH IVUniversity Medical Centre Ljubljanan=302021

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial

CompletedPH IVInsel Gruppe AG, University Hospital Bernn=1222019

A Prospective, Open-Label, Single-Arm, Multi-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis

CompletedPH IChiesi Farmaceutici S.p.A.n=222019

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Blood Loss, Surgical1Coronary Artery Bypass1
Journals, researchers & institutions
Top journals
  • JAMA1
Leading researchers
  • Angiolillo DJ1
  • Brtko M1
  • Cannon L1
  • Chandna H1
  • Dyke C1
  • Firstenberg MS1
  • Hutyra M1
  • Liu T1
Leading institutions
free-text, unnormalised
  • University of Florida1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.